Top Page
Eco Animal Health
(LSE:EAH)
Eco Animal Health (EAH) vs. iShares MSCI United Kingdom ETF (EWC)
Eco Animal Health Business Overview & Revenue Model
Eco Animal Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.60M | 79.60M | 89.42M | 85.31M | 82.19M | 105.61M |
| Gross Profit | 35.91M | 35.91M | 37.68M | 36.75M | 33.70M | 51.54M |
| EBITDA | 7.24M | 7.29M | 6.53M | 7.41M | 3.62M | 18.63M |
| Net Income | 1.69M | 1.69M | 1.05M | 1.01M | -686.00K | 7.34M |
Balance Sheet | ||||||
| Total Assets | 120.60M | 120.60M | 123.27M | 121.31M | 113.60M | 116.89M |
| Cash, Cash Equivalents and Short-Term Investments | 25.01M | 25.01M | 22.37M | 21.66M | 14.31M | 19.52M |
| Total Debt | 3.79M | 3.79M | 4.03M | 4.48M | 1.91M | 1.52M |
| Total Liabilities | 25.84M | 25.84M | 29.89M | 25.76M | 19.25M | 21.57M |
| Stockholders Equity | 85.50M | 85.50M | 83.69M | 83.27M | 82.06M | 81.90M |
Cash Flow | ||||||
| Free Cash Flow | 10.20M | 5.44M | 4.94M | 10.03M | -3.25M | 11.04M |
| Operating Cash Flow | 10.56M | 10.45M | 9.42M | 16.01M | -358.00K | 12.11M |
| Investing Cash Flow | -4.72M | -4.61M | -3.42M | -5.98M | -2.88M | -1.06M |
| Financing Cash Flow | -1.95M | -1.95M | -3.69M | -2.40M | -3.31M | -684.00K |
Eco Animal Health Technical Analysis
Eco Animal Health Peers Comparison
Eco Animal Health Corporate Events
ECO Animal Health Group has received a Positive Opinion from the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use for its ECOVAXXIN® MS poultry vaccine, targeting Mycoplasma synoviae. This milestone is expected to lead to a commercial launch in the EU by mid-2026, marking a significant step in ECO’s growth strategy. The vaccine aims to reduce economic losses in poultry by preventing air-sac and foot-pad lesions, which can decrease egg production. ECO plans to expand its market reach with additional geographic marketing authorizations and further product submissions from its R&D pipeline over the next year.
The most recent analyst rating on (GB:EAH) stock is a Hold with a £89.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.
ECO Animal Health announced the departure of Hafid Benchaoui, the Head of Global R&D, who is leaving to pursue a new opportunity in the companion animal health industry. The company is actively recruiting a new head for its R&D department and assures stakeholders that its R&D pipeline remains on track, supported by an experienced senior team. The transition is expected to be smooth, with Hafid staying until October 21 to ensure a proper handover. This change is not anticipated to disrupt the company’s operations or its market positioning.
The most recent analyst rating on (GB:EAH) stock is a Hold with a £80.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.
ECO Animal Health Group PLC announced that all resolutions proposed at its Annual General Meeting were successfully passed. This outcome reflects strong shareholder support and may positively impact the company’s strategic initiatives and operational stability, reinforcing its position in the global animal health market.
The most recent analyst rating on (GB:EAH) stock is a Hold with a £80.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.
ECO Animal Health Group PLC has reported a robust trading performance for the first half of the financial year ending 30 September 2025, with revenue expected to increase by over 15% compared to the previous year. This growth is driven by significant gains in the China/Japan and North American markets, despite facing currency and tariff challenges. The company anticipates improved gross margins and a substantial rise in adjusted EBITDA, contributing to a more balanced financial performance throughout the year and aligning with market expectations for the full year.
The most recent analyst rating on (GB:EAH) stock is a Hold with a £80.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.
ECO Animal Health Group PLC has appointed Panmure Liberum Limited as a Joint Broker, while Singer Capital Markets continues as the Nominated Adviser and Joint Broker. This strategic move is expected to enhance the company’s market positioning and support its growth trajectory in the global animal health sector.
ECO Animal Health Group PLC has announced the granting of nominal cost conditional share options to its Executive Directors under the company’s Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBS). The LTIP awards, which cover 374,318 ordinary shares, are contingent on meeting performance conditions related to Total Shareholder Return and R&D targets, with a vesting period of three years. Additionally, the DBS awards involve the deferral of 33% of the annual bonuses for the Executive Directors, with options vesting after three years and subject to malice and clawback provisions. These initiatives are part of the company’s strategy to align executive compensation with long-term performance goals and shareholder interests.
ECO Animal Health Group plc has announced the posting of its Annual Report and Accounts for the fiscal year ending 31 March 2025, along with the Notice of Annual General Meeting (AGM) and Form of Proxy to shareholders who opted for hard copies. The AGM is scheduled to be held on 25 September 2025 in London. This announcement underscores the company’s commitment to transparency and shareholder engagement, potentially impacting its market positioning positively by reinforcing investor confidence.
ECO Animal Health Group PLC announced that a special resolution was passed at their recent General Meeting, allowing the trustees of the company’s Employee Benefit Trust to begin limited on-market purchases of the company’s ordinary shares. This move could potentially impact the company’s share value and reflects ECO’s strategic financial decisions to enhance stakeholder value.